{"brief_title": "An Open, Multicenter, Randomized, Dose-Ranging Study of Azithromycin in the Treatment of Disseminated Mycobacterium Avium-Intracellulare Complex Infection (MAC) in Patients With Acquired Immune Deficiency Syndrome (AIDS)", "brief_summary": "To evaluate the efficacy and safety of two doses of azithromycin given chronically for the treatment of Mycobacterium avium bacteremia in AIDS patients.", "condition": "HIV Infections", "intervention_type": "Drug", "intervention_name": "Azithromycin", "criteria": "Inclusion Criteria Concurrent Medication: Allowed: - Medications allowed under a Treatment IND program. Patients must have: - HIV infection. - Disseminated Mycobacterium avium Complex. - Fever (> 100 degrees F) that cannot be attributed to another active infection, and at least one other constitutional symptom (such as fatigue, malaise, anorexia). - Life expectancy of at least the duration of the study. - Consent of parent or guardian if below the legal age of consent. Exclusion Criteria Co-existing Condition: Patients with the following symptoms and conditions are excluded: - Known hypersensitivity or significant intolerance to macrolide antibiotics. - Inability to take oral medications or a current condition likely to interfere with drug absorption (e.g., gastrectomy). Prior Medication: Excluded: - Treatment with an immunostimulant or immunomodulator compound such as alpha-interferon, gamma-interferon, or any interleukin within 7 days prior to study entry. - Any other antibiotic with known activity against M. avium within 7 days prior to study entry. Not expected to comply with the requirements of the protocol, in the opinion of the investigator.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00002090.xml"}